Middle East & Africa Protein A Resin Market Outlook

despite its relatively small geographic size, the middle east and africa (mea) protein a resin market is expected to witness healthy growth over the forecast period (2018-2032). this growth is largely due to the region’s growing healthcare expenditure, which, is expected to substantially augment the growth of advanced protein biopharmaceutical therapeutics – which demand protein a resin for their manufacture. the main use case of protein a resin is for purifying monoclonal antibodies from cell-culture supernatants. to achieve this, the resin binds tightly with immunoglobulin gs (iggs), allowing them to be isolated from the rest of the constituents of the supernatant. this has made the resin a key component in many biopharmaceuticals. however, other than pharmaceutical-production related applications, protein a resins are also used in enzyme-linked immunosorbent assays (elisa), biosensor development, and antibody purification. furthermore, the mea region is also expected to come into focus in hypersulfated chondroitin sulfate production, which requires the use of protein a resin to capture a target protein. compounding the expected growth in demand is the fact that the downfall of the region – due to political and economic uncertainties – is expected to stabilize and, hence, allow companies to make long-term investments in the mea region’s market. the mea region is also expected to see potential collaborations and joint-ventures set up amongst governments and, private players. the middle eastern countries are further expected to move towards levying excise duties on pharmaceuticals, creating a further pool of potential customers for the protein a resin, among medical device manufacturers in the region, who are already in the process of setting up new manufacturing facilities in response to the ongoing fiscal benefits. thus, protein a resin is expected to remain a key component in the mea region’s biopharmaceutical industry over the forecast period. the area’s economic and political stability, and high levels of healthcare spend are expected to further the growth of biopharmaceuticals, in turn keeping demand for protein a resin higher in the mea region.